1
TITLE: AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER plus / human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC)
AUTHORS: Chandarlapaty, S; Linden, HM; Neven, P; Petrakova, K; Bardia, A; Kabos, P; Braga, S; Boni, V; Pelekanou, V; Ternes, N; Gosselin, A; Celanovic, M; Cohen, P; Paux, G; Campone, M;
PUBLISHED: 2021, SOURCE: ANNALS OF ONCOLOGY, VOLUME: 32
INDEXED IN: WOS